Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3565
Name meningioma
Definition A central nervous system cancer that are manifested in the central nervous system and arise from the arachnoid cap cells of the arachnoid villi in the meninges.
Source DiseaseOntology.org
Alt Ids DOID:3554 DOID:1137 DOID:3567 DOID:4750
Path disease disease of cellular proliferation cancer organ system cancer nervous system cancer central nervous system cancer meningioma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown AR-42 meningioma not applicable detail...
Unknown unknown Everolimus + Octreotide meningioma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01880749 Phase I Everolimus Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas Completed
NCT01967823 Phase II Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Completed
NCT02282917 Phase I AR-42 Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma Active, not recruiting
NCT02423525 Phase I Afatinib Safety Study of Afatinib for Brain Cancer Active, not recruiting
NCT02523014 Phase II GSK2256098 Vismodegib A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas Suspended
NCT02648997 Phase II Nivolumab A Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Active, not recruiting
NCT02831257 Phase II Vistusertib AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Active, not recruiting
NCT02847559 Phase II Bevacizumab Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma Recruiting
NCT02933736 Phase 0 Ribociclib Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients Recruiting
NCT03071874 Phase II Vistusertib Phase II Study Of Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas Recruiting
NCT03095248 Phase II Selumetinib Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting
NCT03173950 Phase II Nivolumab Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Recruiting
NCT03220646 Phase II Abemaciclib The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors. Recruiting
NCT03267836 Phase I Avelumab Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma Recruiting
NCT03279692 Phase II Pembrolizumab Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma Recruiting
NCT03604978 Phase Ib/II Ipilimumab + Nivolumab Nivolumab Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Participants With Recurrent Grade II-III Meningioma Recruiting
NCT03971461 Phase II lutetium Lu 177 dotatate Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting
NCT04082520 Phase II lutetium Lu 177 dotatate Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy Recruiting
NCT04283669 Phase II Crizotinib Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas (NF110) Recruiting
NCT04374305 Phase II Brigatinib Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting